World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2024 June 15; 16(6): 2264-2866





Published by Baishideng Publishing Group Inc

World Journal of Gastrointestinal Oncology

Monthly Volume 16 Number 6 June 15, 2024

EDITORIAL

2264	Dual primary gastric and colorectal cancer: The known hereditary causes and underlying mechanisms Azer SA
2271	Application of <i>Fusobacterium nucleatum</i> as a biomarker in gastrointestinal malignancies
	Yu LC, Li YP, Xin YM, Mao M, Pan YX, Qu YX, Luo ZD, Zhang Y, Zhang X
2284	T1 colorectal cancer management in the era of minimally invasive endoscopic resection
	Jiang SX, Zarrin A, Shahidi N
2295	Mixed neuroendocrine and adenocarcinoma of gastrointestinal tract: A complex diagnosis and therapeutic challenge
	Shenoy S
2300	Advancements in breath-based diagnostics for pancreatic cancer: Current insights and future perspectives
	Tez M, Şahingöz E, Martlı HF
2304	Colorectal cancer and dormant metastases: Put to sleep or destroy?
	Senchukova MA
	REVIEW
2318	REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer
2318	REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer <i>Jiang YK, Li W, Qiu YY, Yue M</i>
2318 2335	REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer <i>Jiang YK, Li W, Qiu YY, Yue M</i> Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer
2318 2335	REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer Jiang YK, Li W, Qiu YY, Yue M Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer Shu YJ, Lao B, Qiu YY
2318 2335 2350	 REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer Jiang YK, Li W, Qiu YY, Yue M Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer Shu YJ, Lao B, Qiu YY Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma
2318 2335 2350	REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer <i>Jiang YK, Li W, Qiu YY, Yue M</i> Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer <i>Shu YJ, Lao B, Qiu YY</i> Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma <i>Yao M, Fang RF, Xie Q, Xu M, Sai WL, Yao DF</i>
2318 2335 2350	REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer Jiang YK, Li W, Qiu YY, Yue M Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer Shu YJ, Lao B, Qiu YY Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma Yao M, Fang RF, Xie Q, Xu M, Sai WL, Yao DF
2318 2335 2350 2362	REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer Jiang YK, Li W, Qiu YY, Yue M Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer Shu YJ, Lao B, Qiu YY Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma Yao M, Fang RF, Xie Q, Xu M, Sai WL, Yao DF MINIREVIEWS Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic
2318 2335 2350 2362	REVIEWAdvances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancerJiang YK, Li W, Qiu YY, Yue MResearch progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancerShu YJ, Lao B, Qiu YYEarly monitoring values of oncogenic signalling molecules for hepatocellular carcinoma Yao M, Fang RF, Xie Q, Xu M, Sai WL, Yao DFMINIREVIEWSTherapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer
2318 2335 2350 2362	REVIEW Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer Jiang YK, Li W, Qiu YY, Yue M Research progress of ferroptosis regulating lipid peroxidation and metabolism in occurrence and development of primary liver cancer Shu YJ, Lao B, Qiu YY Early monitoring values of oncogenic signalling molecules for hepatocellular carcinoma Yao M, Fang RF, Xie Q, Xu M, Sai WL, Yao DF MINIREVIEWS Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer Zhou Y, Wu S, Qu FJ

Wang QF, Li ZW, Zhou HF, Zhu KZ, Wang YJ, Wang YQ, Zhang YW



World Journal of Gastrointestinal Oncology

Monthly Volume 16 Number 6 June 15, 2024

2394 Unraveling colorectal cancer prevention: The vitamin D - gut flora - immune system nexus Zhan ZS, Zheng ZS, Shi J, Chen J, Wu SY, Zhang SY

ORIGINAL ARTICLE

Retrospective Cohort Study

2404 Unveiling the secrets of gastrointestinal mucous adenocarcinoma survival after surgery with artificial intelligence: A population-based study

Song J, Yan XX, Zhang FL, Lei YY, Ke ZY, Li F, Zhang K, He YQ, Li W, Li C, Pan YM

2419 Analysis of metabolic characteristics of metabolic syndrome in elderly patients with gastric cancer by nontargeted metabolomics

Zhang H, Shen WB, Chen L

Retrospective Study

2429 Predictive value of preoperative routine examination for the prognosis of patients with pT2N0M0 or pT3N0M0 colorectal cancer

Jing PF, Chen J, Yu ED, Miao CY

2439 Simplified liver imaging reporting and data system for the diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging

Lyu R, Hu WJ, Wang D, Wang J, Ye YB, Jia KF

2449 Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer

An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH

2463 Development of a diagnostic nomogram for alpha-fetoprotein-negative hepatocellular carcinoma based on serological biomarkers

He L, Zhang C, Liu LL, Huang LP, Lu WJ, Zhang YY, Zou DY, Wang YF, Zhang Q, Yang XL

Drug-eluting bead transarterial chemoembolization as neoadjuvant therapy pre-liver transplantation for 2476 advanced-stage hepatocellular carcinoma

Ye ZD, Zhuang L, Song MC, Yang Z, Zhang W, Zhang JF, Cao GH

2487 Association between Helicobacter pylori infection, mismatch repair, HER2 and tumor-infiltrating lymphocytes in gastric cancer

Castaneda CA, Castillo M, Bernabe LA, Sanchez J, Fassan M, Tello K, Wistuba II, Chavez Passiuri I, Ruiz E, Sanchez J, Barreda F, Valdivia D, Bazan Y, Abad-Licham M, Mengoa C, Fuentes H, Montenegro P, Poquioma E, Alatrista R, Flores CJ, Taxa L

2504 Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Pan D, Liu HN, Yao ZY, Chen XX, Li YQ, Zhu JJ, Han ZX, Qin XB

2520 Prediction of pathological complete response and prognosis in locally advanced rectal cancer Xu YJ, Tao D, Qin SB, Xu XY, Yang KW, Xing ZX, Zhou JY, Jiao Y, Wang LL



Monthly Volume 16 Number 6 June 15, 2024

Observational Study

2531 Extrahepatic cholestasis associated with paracoccidioidomycosis: Challenges in the differential diagnosis of biliopancreatic neoplasia

dos Santos JS, de Moura Arrais V, Rosseto Ferreira WJ, Ribeiro Correa Filho R, Brunaldi MO, Kemp R, Sankanrakutty AK, Elias Junior J, Bellissimo-Rodrigues F, Martinez R, Zangiacomi Martinez E, Ardengh JC

Clinical and Translational Research

2541 Development of a novel staging classification for Siewert II adenocarcinoma of the esophagogastric junction after neoadjuvant chemotherapy

Zhang J, Liu H, Yu H, Xu WX

N6-methyladenosine methylation regulates the tumor microenvironment of Epstein-Barr virus-associated 2555 gastric cancer

Zhang Y, Zhou F, Zhang MY, Feng LN, Guan JL, Dong RN, Huang YJ, Xia SH, Liao JZ, Zhao K

2571 Hepatocellular carcinoma: An analysis of the expression status of stress granules and their prognostic value

Ren QS, Sun Q, Cheng SQ, Du LM, Guo PX

- 2592 Comprehensive analysis of clinical and biological value of ING family genes in liver cancer Liu SC
- 2610 Epidemiology and prognostic nomogram for locally advanced gastric signet ring cell carcinoma: A population-based study

Yu ZH, Zhang LM, Dai ZQ, Zhang MN, Zheng SM

Socioeconomic traits and the risk of Barrett's esophagus and gastroesophageal reflux disease: A Mendelian 2631 randomization study

Liu YX, Bin CL, Zhang L, Yang WT, An BP

Basic Study

2646 Complement factor I knockdown inhibits colon cancer development by affecting Wnt/β-catenin/c-Myc signaling pathway and glycolysis

Du YJ, Jiang Y, Hou YM, Shi YB

2663 Fine-needle aspiration technique under endoscopic ultrasound guidance: A technical approach for RNA profiling of pancreatic neoplasms

Seyfedinova SS, Freylikhman OA, Sokolnikova PS, Samochernykh KA, Kostareva AA, Kalinina OV, Solonitsyn EG

2673 Comprehensive analysis of gene mutations and mismatch repair in Chinese colorectal cancer patients Chen H, Jiang RY, Hua Z, Wang XW, Shi XL, Wang Y, Feng QQ, Luo J, Ning W, Shi YF, Zhang DK, Wang B, Jie JZ, Zhong DR

2683 Action of circulating and infiltrating B cells in the immune microenvironment of colorectal cancer by single-cell sequencing analysis

Zhang JP, Yan BZ, Liu J, Wang W



Canton	World Journal of Gastrointestinal Oncology	
Conten	Monthly Volume 16 Number 6 June 15, 2024	
2697	Bidirectional effects of the tryptophan metabolite indole-3-acetaldehyde on colorectal cancer	
	Dai Z, Deng KL, Wang XM, Yang DX, Tang CL, Zhou YP	
2716	Sm-like 5 knockdown inhibits proliferation and promotes apoptosis of colon cancer cells by upregulating p53, CDKN1A and TNFRSF10B	
	Mo CJ, Deng XY, Ma RL, Zhu K, Shi L, Li K	
2727	Shi-pi-xiao-ji formula suppresses hepatocellular carcinoma by reducing cellular stiffness through upregu- lation of acetyl-coA acetyltransferase 1	
	Jian HY, Liang ZC, Wen H, Zhang Z, Zeng PH	
2742	Aspirin suppresses hepatocellular carcinoma progression by inhibiting platelet activity	
	Zhao LJ, Wang ZY, Liu WT, Yu LL, Qi HN, Ren J, Zhang CG	
2757	Circ_0004592: An auxiliary diagnostic biomarker for gastric cancer	
	Kong S, Xu YH, Zheng M, Ju SQ, Shi HC	
2769	N-glycosylation of Wnt3 regulates the progression of hepatocellular carcinoma by affecting Wnt/ β -catenin signal pathway	
	Zhang XZ, Mo XC, Wang ZT, Sun R, Sun DQ	
	SYSTEMATIC REVIEWS	
2781	Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer	
	Wang LM, Zhang WW, Qiu YY, Wang F	
	MFTA-ANALYSIS	
2793	Meta-analysis of transarterial chemoembolization combined with cryoablation vs transarterial chemoembolization alone for \geq 5 cm hepatocellular carcinoma	
	Cheng JF, Sun QL, Tang L, Xu XJ, Huang XZ	
2804	Dynamic contrast enhanced ultrasound in differential diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis	

Esposto G, Santini P, Termite F, Galasso L, Mignini I, Ainora ME, Gasbarrini A, Zocco MA

2816 Correlation analysis of interstitial maturity and prognosis of colorectal cancer: Meta-analysis Liu ZJ, Zhang XW, Liu QQ, Wang SZ

SCIENTOMETRICS

2826 Visualization analysis of research hotspots and trends on gastrointestinal tumor organoids Wang G, Liu T, He WT

2842 Trends and hotspots in gastrointestinal neoplasms risk assessment: A bibliometric analysis from 1984 to 2022

Fu QQ, Ma L, Niu XM, Zhao HX, Ge XH, Jin H, Yu DH, Yang S



World Journal of Gastrointestinal Oncology

Monthly Volume 16 Number 6 June 15, 2024

LETTER TO THE EDITOR

New perspectives in prognostication of hepatocellular carcinoma: The role and clinical implications of 2862 transient receptor potential family genes

Guan SH, Hu WJ, Wang XY, Gu YX, Zhou DH

RETRACTION NOTE

2865 Retraction note to: RNA-binding protein CPSF6 regulates IBSP to affect pyroptosis in gastric cancer

Wang XJ, Liu Y, Ke B, Zhang L, Liang H



World Journal of Gastrointestinal Oncology

Monthly Volume 16 Number 6 June 15, 2024

ABOUT COVER

Editorial Board Member of World Journal of Gastrointestinal Oncology, Samy Azer, FACG, MD, PhD, Professor, Department of Medical Education, King Saud University College of Medicine, Riyadh 11461, Saudi Arabia. azer2000@optusnet.com.au

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-vear IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2023 is 4.2 and Scopus CiteScore rank 2023: Gastroenterology is 80/167; Oncology is 196/404.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Si Zhao; Production Department Director: Xiang Li; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS
World Journal of Gastrointestinal Oncology	https://www.wjgnet.com/bpg/gerinfo/204
ISSN	GUIDELINES FOR ETHICS DOCUMENTS
ISSN 1948-5204 (online)	https://www.wjgnet.com/bpg/GerInfo/287
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
February 15, 2009	https://www.wjgnet.com/bpg/gerinfo/240
FREQUENCY	PUBLICATION ETHICS
Monthly	https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Monjur Ahmed, Florin Burada	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/1948-5204/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
June 15, 2024	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT	ONLINE SUBMISSION
© 2024 Baishideng Publishing Group Inc	https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: office@baishideng.com https://www.wjgnet.com



0 W J

World Journal of **Gastrointestinal** Oncology

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Oncol 2024 June 15; 16(6): 2592-2609

DOI: 10.4251/wjgo.v16.i6.2592

ISSN 1948-5204 (online)

ORIGINAL ARTICLE

Clinical and Translational Research

Comprehensive analysis of clinical and biological value of ING family genes in liver cancer

Shi-Cai Liu

Specialty type: Oncology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade A Novelty: Grade A Creativity or Innovation: Grade A Scientific Significance: Grade A

P-Reviewer: Sultana N, Bangladesh

Received: January 2, 2024 Revised: March 17, 2024 Accepted: April 22, 2024 Published online: June 15, 2024



Shi-Cai Liu, School of Medical Information, Wannan Medical College, Wuhu 241002, Anhui Province, China

Corresponding author: Shi-Cai Liu, PhD, Academic Research, School of Medical Information, Wannan Medical College, No. 22 Wenchang West Road, Higher Education Park, Wuhu 241002, Anhui Province, China. liushicainj@163.com

Abstract

BACKGROUND

Liver cancer (LIHC) is a malignant tumor that occurs in the liver and has a high mortality in cancer. The ING family genes were identified as tumor suppressor genes. Dysregulated expression of these genes can lead to cell cycle arrest, senescence and/or apoptosis. ING family genes are promising targets for anticancer therapy. However, their role in LIHC is still not well understood.

AIM

To have a better understanding of the important roles of ING family members in LIHC.

METHODS

A series of bioinformatics approaches (including gene expression analysis, genetic alteration analysis, survival analysis, immune infiltration analysis, prediction of upstream microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) of ING1, and *ING1*-related gene functional enrichment analysis) was applied to study the expression profile, clinical relationship, prognostic significance and immune infiltration of ING in LIHC. The relationship between ING family genes expression and tumor associated immune checkpoints was investigated in LIHC. The molecular mechanism of *ING1* mediated hepatocarcinogenesis was preliminarily discussed.

RESULTS

mRNA/protein expression of different *ING* family genes in LIHC was analyzed in different databases, showing that ING family genes were highly expressed in LIHC. In 47 samples from 366 LIHC patients, the ING family genes were altered at a rate of 13%. By comprehensively analyzing the expression, clinical pathological parameters and prognostic value of ING family genes, ING1/5 was identified. ING1/5 was related to poor prognosis of LIHC, suggesting that they may play key roles in LIHC tumorigenesis and progression. One of the target miRNAs of ING1 was identified as hsa-miR-214-3p. Two upstream lncRNAs of hsa-miR-214-3p,



U91328.1, and HCG17, were identified. At the same time, we found that the expression of *ING* family genes was correlated with immune cell infiltration and immune checkpoint genes.

CONCLUSION

This study lays a foundation for further research on the potential mechanism and clinical value of *ING* family genes in the treatment and prognosis of LIHC.

Key Words: Liver cancer; ING family genes; Noncoding RNAs; Immune cell infiltration; Prognosis

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Liver cancer (LIHC) is a malignant tumor that occurs in the liver and has a high mortality in cancer. Comprehensive research of expression, mutation, prognosis, and biological mechanisms of *ING* family genes in LIHC is still lacking. We studied the expression profile, clinical relationship, prognostic potential and immune infiltration of *ING* family genes in LIHC. The relationship between *ING* family genes expression and tumor associated immune checkpoints was investigated in LIHC. The molecular mechanism of *ING1*-mediated hepatocarcinogenesis was preliminarily discussed. Our results highlight the potential mechanism and clinical value of *ING* family genes in treatment and prognosis of LIHC.

Citation: Liu SC. Comprehensive analysis of clinical and biological value of *ING* family genes in liver cancer. *World J Gastrointest Oncol* 2024; 16(6): 2592-2609

URL: https://www.wjgnet.com/1948-5204/full/v16/i6/2592.htm **DOI:** https://dx.doi.org/10.4251/wjgo.v16.i6.2592

INTRODUCTION

Liver cancer (LIHC) is a malignant tumor that occurs in the liver and has a high mortality in cancer[1,2]. At present, the main methods to treat LIHC are radiotherapy, chemotherapy, surgery and liver transplantation[3,4]. Recently, although immunotherapy has made significant progress, such as programmed cell death-1 (PD-1) targeted therapy, its prognosis is poor[5]. Therefore, the discovery of new markers is of importance for individualized therapy and effective improvement of prognosis.

The *ING* family genes (*ING1-5*) were identified as tumor suppressor genes[6,7]. Dysregulated expression of these genes can lead to cell cycle arrest, senescence and/or apoptosis[6]. *ING2* is highly expressed in colon cancer and induces colon cancer cells invasion through matrix-metalloproteinase-13-dependent pathway[8]. Studies have shown that knockdown of *ING2* with small interfering RNA (siRNA) leads to premature aging of normal fibroblasts[9], and to apoptosis or cell-cycle arrest of various adherent cancer cells[10]. These findings indicate that *ING2* plays a role in malignant transformation or progression of cancer. Knockdown of *ING5* and *ING4* with siRNA inhibits DNA replication and the transition from G2/M to G1 phase, respectively[11], indicating that *ING4* and *ING5* play a role in cell proliferation. However, the exact effects and the mechanisms of *ING* family genes in the occurrence and development of LIHC are still unclear. Comprehensive research on the expression, mutation and biological mechanisms of *ING* family genes in LIHC is unclear.

In this study, based on several large public databases, the expression profile, clinical relationship, prognostic significance and immune infiltration of *ING* family genes in LIHC were explored. The association of *ING* family genes expression with tumor associated immune checkpoints was investigated in LIHC. The molecular mechanism of *ING1* mediated hepatocarcinogenesis was preliminarily discussed. Our results highlight the potential mechanism and clinical value of *ING* family genes in the treatment and prognosis of LIHC.

MATERIALS AND METHODS

Gene expression analysis

Using the Gene_DE module of Tumor Immune Estimation Resource 2.0 (TIMER2)[12], the expression of *ING* family genes in different cancers in The Cancer Genome Atlas (TCGA) project was analyzed. TIMER2 is freely available at http://timer.cistrome.org/. The University of Alabama at Birmingham Cancer (UALCAN) web-portal[13] was applied to study the expression of *ING* family genes in normal, primary tumor based on clinical pathological parameters, including sample types, individual cancer stages, race, sex, body weight, age, tumor histology, nodal metastasis status, *TP53* mutation status and tumor grade. UALCAN is freely available at https://ualcan.path.uab.edu/. The protein expression data of the Clinical proteomic tumor analysis consortium (CPTAC) was applied to study the expression of ING proteins in normal and primary tumors tissues.

Survival analysis

GEPIA2[14] was applied to acquire significant maps of overall survival (OS) and disease-free survival (DFS) for ING family genes. Patients with LIHC were divided into low-risk and high-risk subgroups based on low (50%) and high (50%) threshold values. The Kaplan-Meier curve was obtained by GEPIA2 survival analysis module. GEPIA2 is freely available at http://gepia2.cancer-pku.cn/.

Genetic alteration analysis

The cBio cancer genomics portal (cBioPortal) is a publicly database that provides resources for analyzing, exploring and visualizing genomics data of cancer[15]. Based on cBioPortal, the LIHC (TCGA, Firehose Legacy) dataset containing 366 samples was selected to explore the ING family genes, and their genetic changes were evaluated. cBioPortal is available at https://www.cbioportal.org/.

Immune infiltration analysis

The Immune-Gene module of TIMER2[12] was applied to visualize the relationship between the expression of ING family genes and the level of immune infiltration in LIHC tissues. The relationship between ING family genes expression and immune checkpoints and immune cell chemotaxis was evaluated.

Prediction of upstream microRNAs and long noncoding RNAs of ING1

The ENCORI/starBase database^[16] is a comprehensive database specifically designed for RNA interactions, which can be applied to predict potential microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) that may bind to ING1 and corresponding miRNAs. The upstream binding miRNAs identification of ING1 was based on these principles: Present in at least five databases including microT, miRanda, miRmap, PicTar, TargetScan, PITA, and RNA22. Co-expression analysis of miRNA-target and RNA-RNA was performed using the Pan-Cancer module. ENCORI is available at https:// rnasysu.com/encori/.

ING1-related gene functional analysis

The STRING database[17] was searched with ING1 and Homo sapiens (main parameters: "experiments", "no more than 50 interactors" in first shell, "evidence"). The experimentally validated ING1 binding proteins were obtained through the above search. Based on the dataset of LIHC tissues in TCGA, the top 100 ING1-related target genes were obtained using the similarity gene detection module of GEPIA2. Using the GEPIA2[14] correlation analysis module, pairwise gene correlation analysis between ING1 and the selected genes was performed. Functional analysis was performed through DAVID[18] to determine the biological function of genes. The P value was adjusted using the Benjamini-Hochberg method, and P < 0.05 was the critical standard. STRING is available at https://string-db.org/.

RESULTS

Expression of ING family genes in LIHC

To study the expression of ING family genes in LIHC, based on multiple databases, mRNA and protein expression was studied. Analysis by TIMER2[12] showed that mRNA expression of the ING family genes was significantly upregulated in LIHC tissues (Figure 1A). ING family genes were also significantly upregulated in other cancers, such as gallbladder cancer, head and neck cancer (Figure 1A). The transcriptional level of ING family genes was further studied using the UALCAN database[13], and similar results were obtained (Figure 1B), which also showed that mRNA expressions of ING family genes was significantly upregulated in LIHC tissues. The gene expression at the protein level is closer to the original manifestation of the disease. Therefore, the protein expression data of LIHC were studied using CPTAC (Figure 1C), which showed that protein expression of ING1/3/4/5 was significantly upregulated in LIHC tissues. This further verified the reliability of these results.

Clinicopathological parameters of ING family genes in LIHC

After comprehensive research of the expression patterns of various ING family genes, we further studied the correlation between mRNA expression of ING family genes and clinical pathologic characteristics such as sex, age, individual cancer stage, race, body weight, and TP53 mutation in LIHC patients. There was a significant difference in the expression of ING2/3/5 between stages 1 and 3, and a significant difference in expression of ING3 between stages 2 and 3 (Figure 2A). Between normal tissues and different pathological stages of LIHC, there were significant differences in the expression of ING family genes. There was no significant difference in the expression of ING family members among different races in LIHC (Figure 2B). There was no significant sex difference in expression of ING family members in patients with LIHC (Figure 2C). There was a significant difference in the expression of *ING5* between normal weight and obese patients with LIHC (Figure 2D). There was a significant difference in the expression of *ING5* between patients aged 41-60 and 61-80 years, and between ages 61-80 and 81-100 years (Figure 2E). The expression of ING2/3/4/5 was significantly different between patients with nonmutated and mutated TP53 (Figure 2F).

The protein expression data of LIHC from the CPTAC database were used to analyze the relationship between the expression of ING family members and the sex and age of patients (Figure 2G and H). There was no significant sex difference in the protein expression of *ING* family members in LIHC patients. There was a significant difference in the expression of ING5 between patients aged 21-40 and 41-60 years, and between 21-40 and 81-100 years. Expression of ING5



WJGO | https://www.wjgnet.com



Liu SC. ING family genes in LIHC

Baishideng®

WJGO https://www.wjgnet.com



Figure 1 Differential expression of *ING* family genes in normal and cancer tissues. A: Expression of *ING* family genes in different tumor types using Tumor Immune Estimation Resource 2.0 (data from The Cancer Genome Atlas); B: Expression of *ING* family genes in liver cancer (LIHC) using the University of Alabama at Birmingham Cancer database; C: Protein expression of *ING* family members in normal and primary LIHC tissues based on the Clinical proteomic tumor analysis consortium dataset. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001.

also differed significantly between patients aged 21-40 and 61-80 years. This study also evaluated the correlation between different *ING* family genes by analyzing their mRNA expression, showing that there was a significant positive correlation among all genes (Figure 2I).

Genetic alteration analysis of ING family genes in LIHC

The genetic changes in the *ING* family genes of LIHC patients were studied using the cBioPortal website. *ING* family genes were altered in 47 samples from 366 patients with LIHC, accounting for a 13% alteration rate (Figure 3). According to TCGA data, the genetic change percentages of *ING1-5* in LIHC were 5%, 4%, 2.7%, 0.8%, and 1.1%, respectively (Figure 3).

Immune cell infiltration of ING family genes in LIHC

Emerging evidence supports the correlation between immune cell levels and the occurrence and progression of multiple types of tumors[19,20]. We explored the relationship between different *ING* members and immune cell infiltration levels in LIHC using TIMER2, which will contribute to the monitoring of immune therapy response in LIHC and the exploration of immune infiltration mechanisms. The expression of *ING1-4* was significantly positively related to neutrophils and CD8+ T cells (Figure 4). Besides, the expression of *ING1-5* was significantly positively related to cancerassociated fibroblasts, B cells, macrophages and myeloid dendritic cells. In addition, the expression of *ING2/3/5* was significantly positively related to CD4+ T cells. Supplementary Figure 1 shows the results in detail.

Correlation between expression of ING family genes and immune checkpoints in LIHC

Immunotherapy based on cytotoxic T lymphocyte-associated antigen (CTLA)-4 and PD-1/PD ligand (PD-L)1 has emerged as a new pillar of LIHC treatment[21,22]. We determined the effect of *ING* gene family expression on LIHC immunotherapy (Figure 5). Expression of *ING2/3/5* in patients with LIHC was significantly positively related to CTLA-4, PD-1, and PD-L1. Expression of *ING4* in LIHC was significantly positively related to PD-L1. Expression of *ING4* was significantly positively related to PD-L1. Expression of *ING4* was significantly positively related to PD-L1. These results suggest that positive expression of *ING* family genes may be a better predictor of immunotherapy response than negative expression. Supplementary Figure 2 shows the results in detail.

Survival analysis of ING family genes in LIHC

To investigate whether expression of *ING* family genes was related to prognosis of LIHC, we explored the prognostic potential of *ING* family genes in cancer using GEPIA2 tool. We were using two prognostic indicators, OS and DFS, to evaluate the prognostic potential of *ING* family genes. In OS analysis, high expression of *ING1/5* indicated poorer survival





WJGO https://www.wjgnet.com

Baishideng®

June 15, 2024 Volume 16 Issue 6



Baishideng® WJGO h

WJGO https://www.wjgnet.com



Figure 2 The relationships between the mRNA/protein expression of ING family members and clinicopathological parameters in liver cancer. A: Between mRNA expression of ING family members and individual cancer stages; B: Between mRNA expression of ING family members and race; C:

Jaishideng® WJGO | https://www.wjgnet.com

June 15, 2024 Volume 16 Issue 6

Between mRNA expression of ING family members and patient sex; D: Between mRNA expression of ING family members and patient body weight; E: Between mRNA expression of ING family members and patient age; F: Between mRNA expression of ING family members and TP53 mutation status; G: Between protein expression of ING family members and patient sex; H: Between protein expression of ING family members and patient age; I: Correlation of mRNA expression in different *ING* family members. ${}^{a}P < 0.05$; ${}^{b}P < 0.01$; ${}^{c}P < 0.001$.

(Figure 6A). DFS analysis showed that high expression of *ING5* was related to poor prognosis (Figure 6B). The remaining ING family members were unrelated to survival time. Therefore, mRNA expression of ING1/5 was significantly related to prognosis of LIHC and could serve as a useful predictive biomarker. Finally, based on comprehensive analysis of the expression, clinicopathological parameters, and prognostic potential of ING family genes, we identified that ING1/5 may play important roles in the occurrence and progression of LIHC.

Upstream miRNAs prediction of ING1

ncRNAs refer to RNA that do not translate to proteins in the transcriptome but regulate gene expression at diversified levels, such as transcription, chromatin structure editing and RNA splicing^[23]. To study whether *ING1* is regulated by ncRNAs, we used the ENCORI database to predict upstream miRNAs that may bind to ING1. Finally, three miRNAs were identified (hsa-miR-193a-3p, hsa-miR-193b-3p, and hsa-miR-214-3p). The results showed that hsa-miR-214-3p negatively regulated ING1 expression with r and P value of -0.143 and 5.80×10^3 , respectively. The overall idea of miRNA and mRNA binding analysis was to find target genes and target miRNAs according to the negative correlation between miRNA expression and target gene expression in view of the targeting relationship between miRNA and mRNA[24]. hsamiR-214-3p was identified as an upstream miRNA that might bind to ING1. We further explored whether hsa-miR-214-3p was involved in the regulation of ING1 expression in LIHC. hsa-miR-214-3p was significantly downregulated in LIHC with $P = 2.11 \times 10^{-15}$ (Figure 7A). We further explored the correlation between hsa-miR-214-3p miRNA expression and clinical pathological characteristics of LIHC. Expression of hsa-miR-214-3p in different pathological stages of LIHC was lower than that in normal tissues, and the same results were shown for other clinicopathological parameters (Figure 7B-G). These results indicated that the regulation of ING1 expression by hsa-miR-214-3p plays a function in the tumorigenesis of LIHC.

Upstream IncRNAs prediction of hsa-miR-214-3p

Using the ENCORI database, the upstream lncRNAs of hsa-miR-214-3p were explored. The differential expression of these lncRNAs in cancer and normal tissues was evaluated using the TCGA database. Only two lncRNAs were finally identified, namely U91328.1 and HCG17. Compared with normal tissue samples, their expression in LIHC was significantly upregulated (Figure 8A). The analysis showed that expression of U91328.1 and HCG17 in normal tissues was lower than that in LIHC tissues at different pathological stages (Figure 8B), and the similar results were found for other clinicopathological parameters (Figure 8B). According to the theory of competing endogenous RNA (ceRNA), IncRNAs can regulate the transcription of target genes by competing with shared miRNAs as ceRNAs[24,25]. Therefore, expression of lncRNA and mRNA must be positively correlated, while expression of miRNA and lncRNA must be negatively correlated. Subsequently, the ENCORI database was used to explore pairwise correlations between mRNAs, lncRNAs and miRNAs to determine collinearity (Figure 8C). Finally, U91328.1 and HCG17 were identified as direct targets of hsamiR-214-3p.

ING1-related partners functional analysis

To further explore the molecular mechanism of *ING1* in the occurrence of LIHC, we screened for targeted *ING1* binding proteins and ING1 expression related genes, and conducted a series of functional analyses. Fifty ING1 binding proteins were obtained using the STRING database[17]. The interaction networks of these proteins were visualized in Figure 9A. Using GEPIA2[14] combined with TCGA LIHC expression data, the top 100 genes related to ING1 expression were obtained. The results indicated that expression of ING1 was positively correlated with expression of TUBGCP3 (r = 0.66), *CARKD* (*r* = 0.61), *ABHD13* (*r* = 0.61), *CUL4A* (*r* = 0.60), and *CREBBP* (*r* = 0.48) (all *P* < 0.001, Figure 9B). An intersection of the two obtained gene sets was taken, and a common gene, CREBBP, was found (Figure 9C). Previous studies have confirmed that CREBBP gene is associated with various cancers (e.g., colorectal and gastric cancer)[26-28]. Therefore, we infer that CREBBP plays a functional role in LIHC.

Functional analysis was performed on all genes in these two datasets. The gene annotation results showed that these genes were mainly correlated with chromatin organization (GO:0006325), regulation of stem cell population maintenance (GO:2000036), nuclear factor-kappaB binding (GO:0051059), p53 binding (GO:0002039), chromosome organization (GO:0051276), programmed cell death (GO:0012501), and transcription factor binding (GO:0008134) (Figure 9D). Pathway annotation showed that these genes were mainly concentrated in 19 pathways (Figure 9E), including hepatitis B (hsa05161), Wnt signaling pathway (hsa04310), Notch signaling pathway (hsa04330) and pathways in cancer (hsa05200). These biological processes, molecular functions and pathways all play vital roles in cancers.

DISCUSSION

LIHC is the leading cause of death from cancer worldwide^[29]. At present, the main methods to treat LIHC are radiotherapy, chemotherapy, surgery and liver transplantation[30]. Although immunotherapy has made significant





Figure 3 Genetic alterations of ING family genes in patients with liver cancer.



Figure 4 Correlation between expression of *ING* family genes and B cells, cancer-associated fibroblasts, myeloid dendritic cells, neutrophils, CD4+ T cells, CD8+ T cells, and macrophage infiltration levels in liver cancer. $^{a}P < 0.05$; $^{b}P < 0.01$; $^{c}P < 0.001$.



Figure 5 Correlation between expression of *ING1* and immune checkpoint genes (*PDCD1*, *CTLA4* and *CD274*) in liver cancer. $^{a}P < 0.05$; $^{b}P < 0.01$; $^{o}P < 0.001$.

Raishideng® WJGO | https://www.wjgnet.com



Figure 6 Correlation between expression of *ING* family genes and prognosis of cancers in The Cancer Genome Atlas using the GEPIA2 tool. A: Overall survival analysis; B: Disease-free survival analysis. The survival chart and Kaplan-Meier curve with positive results were shown. HR: Hazard ratio.

progress, such as PD-1 targeted therapy, prognosis of LIHC remains poor[31]. Therefore, it is urgent to explore the pathogenesis of LIHC and find new therapeutic and prognostic biomarkers. Based on several large public databases, we investigated the expression profile, clinical relationships, prognostic significance, and immune infiltration of *ING* family genes in LIHC.

mRNA/protein expression of different *ING* family genes in LIHC was analyzed in different databases. The mRNA expression of *ING* family genes was significantly upregulated in LIHC tissues and in other cancers, such as gallbladder



Figure 7 Relationships between hsa-miR-214-3p expression and clinicopathological parameters in liver cancer. A: Differential expression of hsa-miR-214-3p between normal and cancer tissue; B: Between expression of hsa-miR-214-3p and individual cancer stages; C: Between expression of hsa-miR-214-3p and patient race; D: Between expression of hsa-miR-214-3p and patient gender; E: Between expression of hsa-miR-214-3p and patient weight; F: Between expression of hsa-miR-214-3p and patient age; G: Between expression of hsa-miR-214-3p and TP53 mutation status. °P < 0.001.

cancer, head and neck cancer. Similar results were obtained using the UALCAN database to further explore the transcription levels of ING family genes. Analysis of protein expression data showed that the ING1/3/4/5 proteins were significantly upregulated in LIHC tissue, verifying the reliability of the results. After comprehensive analysis of expression patterns of ING family genes, we further studied the correlation between mRNA expression of ING family genes and clinical pathologic characteristics in LIHC. Using the LIHC protein expression data in the CPTAC database, we further analyzed the correlation between expression of ING members and the sex and age of patients. We also evaluated the correlation between different ING family genes by analyzing their mRNA expression. There was significant positive correlation among all genes. There is increasing evidence for the important role of ING family genes in different malignancies[8,10,11]. It is reported that the *ING* family genes (*ING1-5*) were identified as tumor suppressor genes[6,7]. Our analysis combined with previous studies suggests that ING1-5 may be biomarker of LIHC.

The genetic alterations of ING family genes in LIHC were explored. The ING family genes were altered in 47 samples from 366 patients with LIHC, accounting for a 13% alteration rate. According to TCGA data, the percentage genetic change of ING1-5 in LIHC were 5%, 4%, 2.7%, 0.8%, and 1.1%, respectively. Immunotherapy has emerged as a promising strategy in LIHC. Tumor-infiltrating immune cells in the tumor microenvironment have a great influence on the responsiveness and effectiveness of such treatments[32]. Therefore, we further investigated the correlation between expression of ING family genes and tumor-infiltrating immune cell infiltration in LIHC tissues. ING1-4 were significantly positively correlated with CD8+ T cells and neutrophils. ING1-5 were significantly positively correlated with cancer-associated fibroblasts, macrophages, B cells and myeloid dendritic cells. ING2/3/5 were significantly positively correlated with CD4+ T cells. The function of ING family genes and their roles in the occurrence and development of LIHC require further explored through clinical and experimental research.

In recent years, immune checkpoint inhibitors (such as CTLA-4, PD-1, and PD-L1 inhibitors) have shown significant therapeutic effects in the clinical treatment of various solid tumors^[22]. However, only a small percentage of cancer patients have shown significant benefits from such drugs[33]. Thus, there is a need to accurately identify patients who could benefit from immune checkpoint inhibitor therapy. To determine the influence of expression of ING family genes on LIHC immunotherapy, we studied the correlation between gene expression and CTLA-4, PD-L1 and PD-1. ING2/3/5 expression was significantly positively correlated with PD-1, PD-L1, and CTLA-4. ING4 expression was significantly positively correlated with PD-1 and PD-L1. ING1 expression was significantly positively correlated with PD-L1. Therefore, these results indicate that positive expression of *ING* family genes is more predictive of immune therapy response than negative expression. The potential mechanism of the correlation between ING family genes and immune checkpoint inhibitors needs to be further explored.

We conducted a survival analysis to explore the prognostic potential of ING family genes. In OS analysis, high expression of ING1/5 indicated poorer survival in LIHC patients. In DFS analysis, high expression of ING5 was related to poor prognosis in LIHC patients. Therefore, the mRNA expression of ING1/5 was significantly related to the prognosis of LIHC and could serve as a useful predictive biomarker. Finally, based on comprehensive analysis of the expression, clinical clinicopathological parameters, and prognostic potential of ING family genes, we identified that ING1/5 may play

Zaishideng® WJGO | https://www.wjgnet.com

Liu SC. ING family genes in LIHC









HCG17





HCG17



HCG17







Saishideng® WJGO https://www.wjgnet.com



Figure 8 Upstream long noncoding RNAs prediction analysis of hsa-miR-214-3p. A: Differential expression of two long noncoding RNAs (IncRNAs) in cancer and normal tissues; B: Expression of two IncRNAs in other clinicopathological parameters; C: Correlation analysis between IncRNAs and *ING1* or between hsa-miR-214-3p and IncRNAs in liver cancer. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001. LIHC: Liver cancer.

vital roles in the occurrence and progression of LIHC.

The current literature mainly focuses on the key functions and roles of the regulatory ncRNAs in the occurrence and progression of cancer. To identify the upstream regulatory miRNA of *ING1*, seven prediction tools were introduced to predict the possible binding miRNA of *ING1*. Three upstream miRNAs of *ING1* were identified. By differential expression and mRNA-miRNA correlation analyses, hsa-miR-214-3p was discovered as the upstream miRNA of *ING1* that affected progression of LIHC. Upstream lncRNAs of the hsa-miR-214-3p/ING1 axis were also identified. Through expression and correlation analyses, U91328.1 and HCG17, which were the two most promising upregulated lncRNAs of hsa-miR-214-3p, were identified. Compared with normal tissue samples, their expression was significantly upregulated in LIHC. The analyses results showed that expression of U91328.1 and HCG17 in LIHC at different pathological stages was higher than that in normal tissue samples, and the similar results were found for other clinicopathological parameters. According to the ceRNA theory, expression of lncRNA and mRNA must be positively correlated, while the expression of miRNA and lncRNA must be negatively correlated. Subsequently, the ENCORI database was used to explore pairwise correlations between mRNAs, lncRNAs and miRNAs to determine collinearity. Finally, U91328.1 and HCG17 were identified as direct targets of hsa-miR-214-3p. The *ING1*/hsa-miR-214-3p/ U91328.1 or HCG17 axis was discovered as a potential regulatory pathway.

aisbideng® WJGO | https://www.wjgnet.com



WJGO https://www.wjgnet.com



Figure 9 Functional analysis of ING1-related genes. A: ING1 binding protein using STRING database; B: Expression correlation between ING1 and selected target genes, including TUBGCP3, CARKD, ABHD13, CUL4A and CREBBP; C: Intersection analysis of the binding genes and associated genes of ING1. List 1: ING1 binding proteins; List 2: Top 100 genes associated with ING1 expression; D: Gene Ontology analysis based on the ING1-binding and interaction genes; E: Kyoto Encyclopedia of Genes and Genomes pathway analysis based on the ING1-binding and interaction genes. BP: Biological processes; CC: Cellular components; MF: Molecular functions; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes.

Ε

KEGG pathway

D

CONCLUSION

This research studied the expression of *ING* family genes in LIHC, showing that *ING* members were highly expressed in LIHC, and ING1/5 were related to poor prognosis. An ncRNA-mediated regulatory mechanism of ING1 in occurrence and development of LIHC (ING1/hsa-miR-214-3p/U91328.1 or HCG17) was constructed. We found that the expression of *ING* family genes was related to immune cell infiltration and to the expression of immune checkpoint genes. Our findings provide new insights into diagnosis, treatment, and prognosis of LIHC.

FOOTNOTES

Author contributions: Liu SC collected and analyzed the data, conceptualized, designed, drafted and revised the manuscript, and approved the final version of the manuscript.

Supported by Talent Scientific Research Start-up Foundation of Wannan Medical College, No. WYRCQD2023045.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: China

ORCID number: Shi-Cai Liu 0000-0003-1270-4729.

S-Editor: Wang JJ L-Editor: A P-Editor: Zhao S

REFERENCES

- 1 Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48 [PMID: 36633525 DOI: 10.3322/caac.21763]
- 2 Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022; 77: 1598-1606 [PMID: 36208844 DOI: 10.1016/j.jhep.2022.08.021]
- Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular 3 carcinoma. Nat Rev Dis Primers 2021; 7: 6 [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3]
- Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. Biosci Trends 2022; 16: 178-188 [PMID: 35732434 DOI: 4 10.5582/bst.2022.01245]
- Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 5 2021; 18: 525-543 [PMID: 33850328 DOI: 10.1038/s41575-021-00438-0]
- Guérillon C, Bigot N, Pedeux R. The ING tumor suppressor genes: status in human tumors. Cancer Lett 2014; 345: 1-16 [PMID: 24333729 6 DOI: 10.1016/j.canlet.2013.11.016]
- Jacquet K, Binda O. ING Proteins: Tumour Suppressors or Oncoproteins. Cancers (Basel) 2021; 13 [PMID: 33925563 DOI: 7 10.3390/cancers13092110
- Kumamoto K, Fujita K, Kurotani R, Saito M, Unoki M, Hagiwara N, Shiga H, Bowman ED, Yanaihara N, Okamura S, Nagashima M, 8 Miyamoto K, Takenoshita S, Yokota J, Harris CC. ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression. Int J Cancer 2009; 125: 1306-1315 [PMID: 19437536 DOI: 10.1002/ijc.24437]
- Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S, Yokota J, Harris CC. Nutlin-3a 9 activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 2008; 68: 3193-3203 [PMID: 18451145 DOI: 10.1158/0008-5472.CAN-07-2780]
- Unoki M, Kumamoto K, Robles AI, Shen JC, Zheng ZM, Harris CC. A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell 10 cycle arrest and apoptosis. FEBS Lett 2008; 582: 3868-3874 [PMID: 18951897 DOI: 10.1016/j.febslet.2008.10.024]
- Doyon Y, Cayrou C, Ullah M, Landry AJ, Côté V, Selleck W, Lane WS, Tan S, Yang XJ, Côté J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2006; 21: 51-64 [PMID: 16387653 DOI: 10.1016/j.molcel.2005.12.007]
- 12 Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 2020; 48: W509-W514 [PMID: 32442275 DOI: 10.1093/nar/gkaa407]
- 13 Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, Creighton CJ, Varambally S. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 2022; 25: 18-27 [PMID: 35078134 DOI: 10.1016/j.neo.2022.01.001]
- 14 Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 2019; 47: W556-W560 [PMID: 31114875 DOI: 10.1093/nar/gkz430]
- 15 Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg



AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404 [PMID: 22588877 DOI: 10.1158/2159-8290.CD-12-0095]

- Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks 16 from large-scale CLIP-Seq data. Nucleic Acids Res 2014; 42: D92-D97 [PMID: 24297251 DOI: 10.1093/nar/gkt1248]
- Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S, Bork P, Jensen LJ, 17 von Mering C. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 2023; 51: D638-D646 [PMID: 36370105 DOI: 10.1093/nar/gkac1000]
- Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: a web server for functional enrichment analysis 18 and functional annotation of gene lists (2021 update). Nucleic Acids Res 2022; 50: W216-W221 [PMID: 35325185 DOI: 10.1093/nar/gkac194]
- Zhu H, Wang G, Zhu H, Xu A. ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors. BMC 19 Cancer 2021; 21: 269 [PMID: 33711961 DOI: 10.1186/s12885-021-07996-1]
- 20 Want MY, Tsuji T, Singh PK, Thorne JL, Matsuzaki J, Karasik E, Gillard B, Cortes Gomez E, Koya RC, Lugade A, Odunsi K, Battaglia S. WHSC1/NSD2 regulates immune infiltration in prostate cancer. J Immunother Cancer 2021; 9 [PMID: 33589522 DOI: 10.1136/iitc-2020-001374]
- Szeto GL, Finley SD. Integrative Approaches to Cancer Immunotherapy. Trends Cancer 2019; 5: 400-410 [PMID: 31311655 DOI: 21 10.1016/j.trecan.2019.05.010]
- 22 Dhasmana A, Dhasmana S, Haque S, Cobos E, Yallapu MM, Chauhan SC. Next-generation immune checkpoint inhibitors as promising functional molecules in cancer therapeutics. Cancer Metastasis Rev 2023; 42: 597-600 [PMID: 37728815 DOI: 10.1007/s10555-023-10139-6]
- Zhou B, Yang H, Yang C, Bao YL, Yang SM, Liu J, Xiao YF. Translation of noncoding RNAs and cancer. Cancer Lett 2021; 497: 89-99 23 [PMID: 33038492 DOI: 10.1016/j.canlet.2020.10.002]
- Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011; 146: 353-24 358 [PMID: 21802130 DOI: 10.1016/j.cell.2011.07.014]
- Wang P, Guo Q, Hao Y, Liu Q, Gao Y, Zhi H, Li X, Shang S, Guo S, Zhang Y, Ning S, Li X. LnCeCell: a comprehensive database of 25 predicted lncRNA-associated ceRNA networks at single-cell resolution. Nucleic Acids Res 2021; 49: D125-D133 [PMID: 33219686 DOI: 10.1093/nar/gkaa1017
- Schoof M, Epplen GD, Walter C, Ballast A, Holdhof D, Göbel C, Neyazi S, Varghese J, Albert TK, Kerl K, Schüller U. The tumor suppressor 26 CREBBP and the oncogene MYCN cooperate to induce malignant brain tumors in mice. Oncogenesis 2023; 12: 36 [PMID: 37407554 DOI: 10.1038/s41389-023-00481-3
- Yang J, Zhao S, Su J, Liu S, Wu Z, Ma W, Tang M, Wu J, Mao E, Han L, Liu M, Zhang J, Cao L, Shao J, Shang Y. Comprehensive genomic 27 profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer. Front Oncol 2023; 13: 1285508 [PMID: 38023196 DOI: 10.3389/fonc.2023.1285508]
- Jiang Q, Miao J, Wu F, Li F, Zhang J, Jing X, Cai S, Ma X, Wang X, Zhao L, Huang C. RNF6 promotes gastric cancer progression by 28 regulating CCNA1/CREBBP transcription. Cell Cycle 2023; 22: 2018-2037 [PMID: 37904524 DOI: 10.1080/15384101.2023.2275899]
- Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology 2023; 29 77: 1773-1796 [PMID: 35989535 DOI: 10.1002/hep.32740]
- Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, Pawlik TM. Management of Hepatocellular Carcinoma: A Review. 30 JAMA Surg 2023; 158: 410-420 [PMID: 36790767 DOI: 10.1001/jamasurg.2022.7989]
- Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for 31 hepatocellular carcinoma. Nat Rev Clin Oncol 2022; 19: 151-172 [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2]
- Guo Y, Yang J, Ren K, Tian X, Gao H, Tian X, Zhang X, Kan Q. The Heterogeneity of Immune Cell Infiltration Landscape and Its 32 Immunotherapeutic Implications in Hepatocellular Carcinoma. Front Immunol 2022; 13: 861525 [PMID: 35355983 DOI: 10.3389/fimmu.2022.861525]
- Banday AH, Abdalla M. Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. Curr Med Chem 2023; 30: 3215-33 3237 [PMID: 35986535 DOI: 10.2174/0929867329666220819115849]



WJGO | https://www.wjgnet.com



Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: office@baishideng.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

